Neuroendocrine cancer with mets,
Conținutul
One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy.
NEUROENDOCRINE TUMORS: CHOOSING APPROPRIATE IMAGING METHODS | The Medical-Surgical Journal
Some of the drugs that are used for NETs as somatostatin analogs for neuroendocrine cancer with mets octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Neuroendocrine cancer with mets. All the patients had at least one assay per year. The dose of octreotide varied from 20 to 50 mg, monthly.
The fasting glucose insignificantly changed from baseline after 2 years.
Psychosocial Aspects of Living with Neuroendocrine Cancer: Patient/Caregiver Panel
No new case of diabetes was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period. The chromogranin A had sustained high values for all the 9 cases, marking the disease progression. The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the neuroendocrine cancer with mets of NETs, yet they are not correlated.
Rezumat Tumorile neuroendocrine NET sunt mult mai frecvente în ultimele decade. Unul din intrumentele majore de evaluare în această patologie vindecare cancer sange reprezentat de dozarea markerilor neuroendocrini precum cromogranina A, serotonina, acidul 5-hidroxi indolacetic urinar şi enolaza neuronal specifică. Aceştia se schimbă cu progresia tumorală, indiferent de terapie.
O parte din medicamentele folosite în NET precum analogii de somatostatin de exemplu, octreotid interferă neuroendocrine cancer with mets metabolismul glucozei. Am analizat într-un studiu retrospectiv de-a lungul a 2 ani dinamica markerilor NET şi profilul glicemic.
This article provides an overview of the current state of the imaging modalities used for primary tumor visualization, staging and follow-up. Detection of NETs and patient monitoring relies mainly on anatomical imaging such as computed tomography CTmagnetic resonance imaging MRIand ultrasonography US under certain conditions. Molecular imaging techniques in combination with CT or MRI hybrid imaging greatly benefit patient management, including better localization of occult tumors and better staging. Diagnosis of patients with NETs is a complex process and, it is unlikely that any single diagnostic modality to be effective. Thus, NET diagnosis is a process utilizing a variety of methods including blood, urine and tumor tissue samples in combination with anatomical or hybrid imaging for localization, delineation and staging of the disease.
Material si metode. Toţi pacienţii au avut cel puţin o evaluare pe an. Doza de octreotid a variat de la 20 la 50 mg lunar.
Services on Demand
Glicemia s-a modificat nesemnificativ de la bază după 2 ani. Nu s-a înregistrat nici un caz nou de diabet. O pacientă a necesitat insulină pentru diabetul preexistent dar între timp s-a adaugat şi terapie cu interferon Cromogranina A a avut valori mari sustinute pentru toate cele 9 cazuri, sugerând progresia bolii.
Enolaza neuronal specifică a crescut semnificativ iar serotonina serică neuroendocrine cancer with mets 5HIIA au crescut considerabil în 2 cazuri cu simptome severe de sindrom carcinoid. Markerii NET şi metabolismul glucidic sunt instrumente foarte utile in managementul tumorilor neuroendocrine, totusi acestea nu se coreleaza. Cuvinte cheie: cromogranina A ; tumora neuroendocrina recidiva oxiuri serotonina References 1.
Most Downloaded Articles
Neuroendocrine tumors. Endocr Relat Cancer.
DOI: Oberndorfer S. Karzinoide tumoren des dunndarms.
MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, with findings being consensually described focusing on changes observed at computed tomography. Only one typical carcinoid presented the characteristic appearance of central endobronchial nodule with distal pulmonary atelectasis, while the others were pulmonary nodules or masses. The atypical carcinoids corresponded to peripheral heterogeneous masses. One out of the three LCNCs was a peripheral homogeneous mass, while the others were ill-defined and heterogeneous.
Frank Z Pathol. Google Scholar 3. Carcinoid Tumors.
- Hpv impfung zurich
- Vermox vs helmintox
- Cancer hormonal de mama
- Rectal cancer lump
Как всегда, не терпится.
Еще несколько метров, и Олвину уже представилось, будто он стоит прямо в воздухе, без какой-либо видимой поддержки.
- Cancer pulmonar etiologia
Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol.
Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Regul Pept.
Не было необходимости тратить месяцы и годы, исследуя Диаспар изнутри, комнату за комнатой, коридор за коридором.
The poor prognosis factors in G2 neuroendocrine tumor. Rom Neuroendocrine cancer with mets Morphol Embryol. Google Scholar The dedifferentiation of neuroendocrine tumor metastases: myth or reality? PubMed Google Scholar Octreotide for the treatment of hypoglycemia after insulin glargine overdose.
J Emerg Med. Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Acta Oncol.
Revista Romana de Medicina de Laborator
Long-term clinical outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol.
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.
